| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Phase 3 topline data readout example | Phase 3 | — | Subscribe to access the data. | Biologics | Endocrine System | ||
Phase 3 topline data readout example | Phase 3 | — | Subscribe to access the data. | Biologics | Endocrine System | ||
Phase 3 topline data readout example | Phase 3 | — | Subscribe to access the data. | Biologics | Endocrine System |
Recent Updates
Recently added Catalysts
Rezolute, Inc.$4.75
-0.38 (-7.41%)
D 29Pipeline Score Richly Valued Pharma · Clinical
Market Cap
312.95 M
EPS
-0.81
P/E Ratio
-
Value Trade
22.64 M
SEC Financials
Q1 2026Dilution Risk
R&D Expenses
11.41 M
Total Assets
125.46 M
Total Liabilities
8.63 M
Equity
116.83 M
D/E Ratio
12,345
-2.69 %
Week
-1.22 %
1 Month
-1.22 %
3 Month
-65.61 %
6 Month
-50.08 %
5 Year
-98.16 %
All Time
Cash Data
Cash Position
120.27 M
Monthly Burn
5.79 M
Runway
18.8 mo
Burn Trend
SEC Filing
May 12, 2026
Overview
Volume
2.21 M
52 Week Range
1.07 - 11.46
% held by Insiders
16.51 %
% held by Institutions
86.2 %
Enterprise Value
193.79 M
Total Shares
95.65 M
Short %
20.06 %
Float Shares
81.78 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Rezolute, Inc.
319Total events
4Upcoming
59Tier-1 (high impact)
2013 – 2026Coverage
Upcoming catalysts 4
Event history 315
Q3 2026
◆Topline ReadoutErsodetugClinical Data
Topline results from Phase 3 upLIFT study expected in second half of 2026
tumor hyperinsulinismsource ↗
Q3 2026
◆Timing GuidanceErsodetugPresentation
Update on congenital HI program expected in second half of 2026
congenital hyperinsulinismsource ↗
Jun 17, 2026
▲Poster PresentationErsodetugPresentation
Poster presentation of case series from EAP in tumor HI
tumor hyperinsulinismsource ↗
Jun 17, 2026
●Oral PresentationErsodetugPresentation
Oral presentation of previously reported sunRIZE results
congenital hyperinsulinismsource ↗
Jun 17, 2026
▲Interim AnalysisErsodetugTrial
Interim and preliminary Phase 3 upLIFT study observations in tumor HI
tumor hyperinsulinismsource ↗
Jun 15, 2026
◆Poster PresentationPresentation
Poster presentation on outcomes in congenital hyperinsulinism systematic review at ENDO 2026
congenital hyperinsulinismsource ↗
Jun 13, 2026
◆Oral PresentationErsodetugPresentation
Oral presentation of top-line results from Phase 3 sunRIZE study of ersodetug in congenital hyperinsulinism at ENDO 2026
congenital hyperinsulinismsource ↗
Jun 13, 2026
◆Poster PresentationErsodetugPresentation
Poster presentation on compassionate use of ersodetug in patients with malignant insulin-secreting tumors at ENDO 2026
refractory hypoglycemia due to malignant insulin-secreting tumorssource ↗
Jun 13, 2026
◆Poster PresentationPresentation
Poster presentation on association of early-life hypoglycemia with neurological outcomes in congenital hyperinsulinism at ENDO 2026
congenital hyperinsulinismsource ↗
Jun 2, 2026
▲Interim AnalysisErsodetugTrial
Interim data: 6 of 8 participants met primary endpoint responder criterion
tumor hyperinsulinismsource ↗
Jun 2, 2026
●Enrollment UpdateErsodetugTrial
Midway through enrollment of planned 16 participants; 8 enrolled to date
tumor hyperinsulinismsource ↗
Drug Pipeline Intelligence
D29
Pipeline Score $26M
Pipeline ValueRichly Valued
Valuation Signal2
Drugs Scored0.1x
rNPV / MCap Top 32%
Micro Cap (rank 621 of 912)
Percentile RankRezolute, Inc. faces pipeline headwinds (29/100), with $123M risk-adjusted pipeline value, led by Experimental: Group 1 - RZ402 in Diabetic Macular Edema (Phase 2).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Experimental: Group 1 - RZ402 Small molecule | Diabetic Macular Edema | Phase 2 | NCT05712720 | 14% | $123M | COMPLETED | 94 | - | - | Apr 11, 2024 | - | Oct 3, 2025 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
ersodetug BreakthroughOrphan | congenital hyperinsulinism | Phase 3 | 2026-06-17 | In a case series from the Expanded Access Program, 75% of 9 patients with refractory hypoglycemia due to malignant insulinoma and non-islet cell tumors achieved complete discontinuation of IV dextrose/total parenteral nutrition. Read More | Rezolute Highlights Results Presented from Natural History Outcomes Studies and its Ersodetug Clinical Program in Hyperinsulinism at Annual Meeting of the Endocrine Society Read More | |
ersodetug BreakthroughOrphan | congenital hyperinsulinism | Phase 3 | 2026-06-17 | In a case series from the Expanded Access Program, 75% of 9 patients with refractory hypoglycemia due to malignant insulinoma and non-islet cell tumors achieved complete discontinuation of IV dextrose/total parenteral nutrition. Read More | Rezolute Highlights Results Presented from Natural History Outcomes Studies and its Ersodetug Clinical Program in Hyperinsulinism at Annual Meeting of the Endocrine Society Read More | |
ersodetug BreakthroughOrphan | congenital hyperinsulinism | Phase 3 | 2026-06-17 | In a case series from the Expanded Access Program, 75% of 9 patients with refractory hypoglycemia due to malignant insulinoma and non-islet cell tumors achieved complete discontinuation of IV dextrose/total parenteral nutrition. Read More | Rezolute Highlights Results Presented from Natural History Outcomes Studies and its Ersodetug Clinical Program in Hyperinsulinism at Annual Meeting of the Endocrine Society Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in RZLT
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
RZLT Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
RZLTRezolute Highlights Results Presented from Natural History Outcomes Studies and its Ersodetug Clinical Program in Hyperinsulinism at Annual Meeting of the Endocrine Society
Rezolute, Inc. presented key findings at the Annual Meeting of the Endocrine Society, focusing on congenital hyperinsulinism and the clinical program for ersodetug. The presentations included analyses of natural history and adverse outcomes, as well as positive results from a case series in tumor hyperinsulinism. The data supports the therapeutic benefits of ersodetug and highlights the urgent need for improved treatment options.
Read more →RZLTRezolute Announces Four Presentations at the Upcoming Annual Meeting of the Endocrine Society
Rezolute, Inc. announced that it will be presenting four studies at the upcoming Annual Meeting of the Endocrine Society in Chicago, focusing on its investigational therapy, ersodetug, for treating congenital hyperinsulinism. The presentations include an oral overview of the Phase 3 sunRIZE study's interim results and various poster presentations detailing the natural history of the disease and outcomes from clinical use of ersodetug. Despite not meeting all primary endpoints in the sunRIZE study, there were nominal improvements noted, and the FDA is set to review comprehensive analysis datasets from the company.
Read more →RZLT▲ +10.8%on this news· ran to +27% by day 1shared move
Rezolute Announces Positive Interim Data for its Phase 3 upLIFT Study of Ersodetug in Tumor Hyperinsulinism
Rezolute, Inc. has reported positive interim data from its Phase 3 upLIFT study of ersodetug for tumor hyperinsulinism. Currently, 50% of the study's participants are enrolled, with 6 out of 8 meeting the primary endpoint of reducing intravenous glucose requirements. The study is expected to conclude with topline results in the second half of 2026.
Read more →RZLT▲ +10.8%on this news· ran to +27% by day 1shared move
Positive Interim Data for its Phase 3 upLIFT Study of Ersodetug in Tumor Hyperinsulinism
Rezolute, Inc. announced positive interim data from its Phase 3 upLIFT study of ersodetug for treating tumor hyperinsulinism. Out of eight participants enrolled so far, six achieved significant reductions in their intravenous glucose requirements, supporting the drug's promising efficacy. The study remains ongoing, with full results expected in late 2026. Despite the positive findings, the withdrawal of a participant due to health complications underscores ongoing challenges in this patient population.
Read more →RZLTRezolute Reports Third Quarter Fiscal 2026 Financial Results and Provides Business Update
Rezolute, Inc. reported its financial results for Q3 fiscal 2026, highlighting positive outcomes from the Phase 3 sunRIZE study of ersodetug for congenital hyperinsulinism. The study showed significant improvements in glycemic control compared to placebo. The FDA acknowledged challenges in the study and encouraged further analysis, with an update expected in the second half of 2026.
Read more →RZLTRezolute to Participate in Upcoming Investor Conferences
Rezolute, Inc. announced its participation in upcoming investor conferences, specifically the H.C. Wainwright 4th Annual BioConnect Investor Conference and the Jefferies Global Healthcare Conference, scheduled for June 2-4, 2026. The company, which focuses on treating hypoglycemia due to hyperinsulinism, will engage in fireside chats and one-on-one meetings with investors. This participation reflects Rezolute's commitment to enhancing its investor relations and showcasing its therapeutic advancements.
Read more →RZLTRezolute Announces Oral Presentation of Results From its Phase 3 sunRIZE Study of Ersodetug in Patients with Congenital Hyperinsulinism at the Pediatric Endocrine Society Annual Meeting Includes results from additional c
Rezolute, Inc. presented favorable results from its Phase 3 sunRIZE study of ersodetug for congenital hyperinsulinism at the Pediatric Endocrine Society Annual Meeting. The study demonstrated significant glycemic control improvements compared to placebo, though the primary endpoint was not met. High participation rates in the open-label extension phase suggest sustained treatment benefits. The company plans to align with the FDA on the future of the study following recent discussions regarding study endpoints.
Read more →RZLTRezolute, Inc. Investigated by the Portnoy Law Firm
The Portnoy Law Firm has launched an investigation into Rezolute, Inc. for possible securities fraud following a significant drop in the company's stock price. The decline, amounting to 87.2%, was influenced by the disappointing results from a Phase 3 study of its lead product, ersodetug, which failed to meet critical efficacy measures. Investors are being encouraged to assess their legal options as the firm considers filing a class-action lawsuit on behalf of affected shareholders. The company's diminished prospects have raised concerns about its future performance.
Read more →RZLTRezolute to Present Results from its Phase 3 sunRIZE Study in Congenital Hyperinsulinism at the Pediatric Endocrine Society (PES) Annual Meeting
Rezolute, Inc. announced that it will present results from its Phase 3 sunRIZE study of ersodetug in congenital hyperinsulinism at the Pediatric Endocrine Society Annual Meeting. The presentation will include previously announced topline results and additional data updates. The study evaluated ersodetug's efficacy and safety for patients experiencing hypoglycemia, demonstrating promising engagement and potential therapeutic benefits. Enrollment included 63 participants from various countries, showcasing a global interest in the treatment's impact on this rare disease.
Read more →RZLT▲ +12.1%on this news· ran to +33% by day 1
Rezolute Provides Update on its Congenital Hyperinsulinism Program Following FDA Meeting
Rezolute, Inc. provided an update on its congenital hyperinsulinism program following a recent FDA meeting. The sunRIZE study showed reductions in hypoglycemia events, but did not meet its primary endpoint due to statistical insignificance. However, the FDA acknowledged the challenges faced and encouraged further analysis. Rezolute is optimistic about the potential for advancing its treatment, ersodetug, based on the feedback received.
Read more →RZLT▲ +6.1%on this news
Rezolute to Participate in the Citizens Life Sciences Conference
Rezolute, Inc. will participate in the Citizens Life Sciences Conference on March 10-11, 2026, in Miami, FL. The company focuses on treating hypoglycemia caused by hyperinsulinism and will conduct one-on-one investor meetings during the event. This engagement highlights Rezolute's commitment to investor relations and its innovative treatment approach.
Read more →RZLT▲ +7.7%on this news
Rezolute Reports Second Quarter Fiscal 2026 Financial Results and Provides Business Update
Rezolute, Inc. has announced its financial results for the second quarter of fiscal 2026, reporting a net loss of $22.8 million, a significant increase from the previous year's loss of $15.7 million. The company experienced heightened research and development costs, attributed to clinical trial activities and severance related to workforce reductions. As of December 31, 2025, Rezolute's cash and cash equivalents stood at $132.9 million, although overall investments decreased from earlier in the year. The company's focused therapeutic, ersodetug, continues to be studied for its application in treating hypoglycemia caused by hyperinsulinism.
Read more →RZLTRezolute, Inc. (RZLT) Shares Tank 90% Amid Lead Asset Trial Failure -- Hagens Berman Investigating
Rezolute, Inc. experienced a dramatic decline in share value, plummeting by as much as 90% after the failed Phase 3 sunRIZE trial for its drug, ersodetug, intended to treat hypoglycemia from hyperinsulinism. The study's results did not demonstrate statistically significant improvements in reducing hypoglycemic events compared to placebo. Amid investor concern, the law firm Hagens Berman is probing whether the company misled shareholders regarding the drug's potential efficacy and market opportunities. Analysts have also downgraded their ratings on the stock sharply, reflecting the negative shift in investor sentiment.
Read more →RZLT▼ -7.6%on this newsshared move
Rezolute to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026
Rezolute, Inc. will participate in the Guggenheim Emerging Outlook: Biotech Summit 2026 on February 11-12 in New York. The company, which specializes in treating hypoglycemia from hyperinsulinism, will engage in one-on-one meetings with investors. This event offers an opportunity for Rezolute to showcase its innovative therapies and connect with potential investors.
Read more →RZLT▲ +23%on this news
Rezolute Provides Insights from its Phase 3 sunRIZE Study in Congenital Hyperinsulinism and Shares Findings from its Expanded Access Program in Tumor Hyperinsulinism
Rezolute, Inc. provided insights from its Phase 3 sunRIZE study and Expanded Access Program for ersodetug in congenital and tumor hyperinsulinism. Although the sunRIZE study did not meet its primary endpoints, the company believes the data supports ersodetug's activity. Rezolute plans to meet with the FDA to discuss the path forward for congenital hyperinsulinism.
Read more →RZLTREZOLUTE INVESTIGATION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of RZLT
Faruqi & Faruqi, LLP is investigating potential claims on behalf of investors in Rezolute, Inc. following a significant drop in the company's stock price. On December 11, 2025, Rezolute shares lost around 85-90% of their value after its Phase 3 clinical trial for ersodetug did not meet primary or secondary endpoints. Investors are encouraged to contact the law firm to discuss their legal rights and options after these disappointing results.
Read more →RZLT▼ -87.2%on this newsshared move
Rezolute Announces Phase 3 sunRIZE Study Results in Congenital Hyperinsulinism
Rezolute announced that its Phase 3 sunRIZE study of ersodetug for congenital hyperinsulinism did not meet its primary or key secondary endpoints. Although a 45% reduction in hypoglycemia events was observed at the highest dose, it was not statistically significant compared to the placebo. Safety observations were generally favorable, but some participants experienced serious allergic reactions.
Read more →RZLTRezolute Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Rezolute, Inc. has announced the granting of equity inducement awards to two new employees as part of their hiring process. The awards, which total 245,000 stock options, were approved by the Compensation Committee under Nasdaq Listing Rule 5635(c)(4). The options will vest over four years and have a 10-year term with an exercise price of $9.32.
Read more →RZLT▼ -7.5%on this newsshared move
Rezolute Investor Event: Ersodetug Development Program
Rezolute, Inc. recently held an investor event to discuss the development program for Ersodetug (RZ 358), aimed at addressing congenital and tumor hyperinsulinism. The event, led by key executives and medical experts, focused on the significant unmet clinical needs in managing hypoglycemia associated with these conditions. The company emphasized the promising potential of RZ 358 to improve treatment outcomes, and outlined their ongoing clinical studies and efforts to advance this therapy. Challenges related to existing therapies were acknowledged, highlighting the urgency for better management options.
Read more →RZLT▲ +12.1%on this newsshared move
Rezolute Reports First Quarter Fiscal 2026 Financial Results and Provides Business Update
Rezolute, Inc. reported its financial results for Q1 Fiscal 2026, highlighting progress in its clinical trials for hyperinsulinism. The company anticipates topline results from the Phase 3 sunRIZE trial in December and is currently enrolling patients for a streamlined Phase 3 trial in tumor hyperinsulinism. Despite an increase in net loss, Rezolute remains focused on advancing its antibody therapy, ersodetug.
Read more →RZLT▲ +5.1%on this newsshared move
Rezolute to Host Virtual Investor Event on Ersodetug Development Program
Rezolute, Inc. will host a virtual investor event on November 10, 2025, to discuss the development of ersodetug, a treatment for hypoglycemia due to hyperinsulinism. The event will cover the market opportunity and clinical progress of ersodetug, currently in two Phase 3 studies. Key insights will be shared by Rezolute's management and hyperinsulinism experts.
Read more →RZLTRezolute Reports Fourth Quarter and Full Year Fiscal 2025 Financial Results and Provides Business Update
Rezolute, Inc. reported its financial results for the fourth quarter and full year ended June 30, 2025, revealing a net loss of $74.4 million compared to the previous year's loss of $68.5 million. The company highlighted advancements in its pipeline, particularly for its therapy, ersodetug, targeting hyperinsulinism. Notably, Rezolute is on track to report topline results from the sunRIZE trial in December 2025. Additionally, the firm maintains a solid cash position of $167.9 million, allowing for continued progress in clinical research and development.
Read more →RZLTRezolute Announces Alignment with FDA on Streamlined Design for Ongoing Phase 3 Trial of Ersodetug in Tumor Hyperinsulinism
Rezolute, Inc. has announced alignment with the FDA on a streamlined design for its ongoing Phase 3 trial of ersodetug, aimed at treating hypoglycemia caused by tumor hyperinsulinism. The revised study will involve as few as 16 participants and eliminate the need for a double-blind randomized placebo-controlled trial. Topline data is expected in late 2026, with the FDA recognizing the broader applicability of ersodetug.
Read more →RZLTRezolute Appoints Seasoned Commercial Executive Sunil Karnawat as Chief Commercial Officer
Rezolute, Inc. has appointed Sunil Karnawat as Chief Commercial Officer, effective August 18, 2025. Karnawat brings over 25 years of experience in biopharmaceutical commercialization, having successfully launched multiple therapies for ultra-rare diseases. His leadership is expected to be crucial as the company advances its therapy, ersodetug, through Phase 3 studies for hyperinsulinism.
Read more →RZLTRezolute to Participate in the BTIG Virtual Biotechnology Conference
Rezolute, Inc. will participate in the BTIG Virtual Biotechnology Conference on July 29-30, 2025. The company's management will hold one-on-one investor meetings during the event. Rezolute focuses on treating hypoglycemia caused by hyperinsulinism with its antibody therapy, ersodetug, which has demonstrated significant benefits in clinical trials.
Read more →RZLTBaseline demographics and disease characteristics were consistent with published epidemiology for this population. The extent of disease burden underscores the inadequacy of current SOC options which have lacked innovati
The article discusses the ongoing Phase 3 study (sunRIZE) of ersodetug (RZ358), an insulin receptor antibody targeted for congenital hyperinsulinism. Preliminary demographics indicate that the enrolled participants, averaging 3.4 years of age, face significant hypoglycemia burdens despite existing treatments. The study aims to evaluate the efficacy of ersodetug, which has shown a promising dose-responsive improvement in hypoglycemia events. FDA has recognized its potential by granting Breakthrough Designation, while concerns remain about the inadequacy of current treatment options.
Read more →RZLT▲ +6.2%on this news
Rezolute Announces Presentation of Participant Baseline Data from its Fully Enrolled Phase 3 Study of Ersodetug in Congenital Hyperinsulinism at the Upcoming Annual Meeting of the Endocrine Society (ENDO 2025)
Rezolute, Inc. announced that a presentation regarding participant baseline data from its fully enrolled Phase 3 study of ersodetug will take place at ENDO 2025. The study aims to evaluate the efficacy and safety of ersodetug for patients suffering from congenital hyperinsulinism who are experiencing hypoglycemia. With the completion of enrollment, the company is poised to share insights into the study population and expects to release topline data in December. The treatment has shown promise in addressing the significant unmet medical need in this patient population.
Read more →RZLTRezolute Announces Completion of Enrollment in the Phase 3 sunRIZE Study of Ersodetug in Patients with Congenital Hyperinsulinism
Rezolute, Inc. has announced the completion of enrollment for its Phase 3 sunRIZE study, which aims to assess the efficacy and safety of ersodetug in treating congenital hyperinsulinism. The study exceeded its target enrollment with 62 participants, approximately 15% from U.S. sites. Topline data is expected in December 2025, and if favorable, the company plans to submit a Biologics License Application to the FDA in 2026. Ceasing hypoglycemic episodes in patients through this treatment is a critical objective of the study.
Read more →RZLTRezolute Reports Third Quarter Fiscal 2025 Financial Results and Provides Business Update sunRIZE enrollment on track including U.S. sites and expected to be completed in May 2025; topline data anticipated in December 20
Rezolute, Inc. announced its financial results for the third quarter of fiscal 2025, reporting an increase in investments in research and development, alongside a notable loss of $18.9 million. The company provided updates on its sunRIZE study, which is on track for enrollment completion by May 2025, and anticipates topline data in December 2025. Furthermore, the FDA granted Breakthrough Therapy Designation to its therapy, ersodetug, aimed at treating hypoglycemia related to hyperinsulinism, demonstrating potential for across-the-board efficacy in treating the condition.
Read more →RZLTRezolute Reports Third Quarter Fiscal 2025 Financial Results and Provides Business Update
Rezolute, Inc. reported its financial results for Q3 fiscal 2025, highlighting progress in its clinical trials for hypoglycemia treatments. The FDA granted Breakthrough Therapy Designation for ersodetug, which is being evaluated in the Phase 3 sunRIZE study. The company expects to complete enrollment by May 2025 and anticipates topline results in December 2025. Despite a net loss increase, Rezolute's cash runway has been extended to support ongoing research and development.
Read more →RZLTRezolute Receives Breakthrough Therapy Designation from FDA for Ersodetug in the Treatment of Hypoglycemia Due to Tumor Hyperinsulinism
Rezolute, Inc. has received Breakthrough Therapy Designation from the FDA for its investigational therapy, ersodetug, targeting hypoglycemia caused by tumor hyperinsulinism. The designation highlights the urgent need for effective treatments for severe hypoglycemia in oncology. This approval is based on the therapy's clinical trial data and real-world success in treating patients. A registrational study is set to commence mid-2025, aiming for topline results in late 2026.
Read more →RZLTRezolute, Inc. Announces Closing of Underwritten Offering
Rezolute, Inc. has successfully closed an underwritten offering of 24,940,769 shares at $3.25 each, raising approximately $96.9 million. The funds will be allocated for research and development, corporate expenses, and working capital. The offering saw participation from various investors and included a private placement expected to close soon.
Read more →RZLTRezolute, Inc. Announces Closing of Underwritten Offering NEW YORK-(BUSINESS WIRE)
Rezolute, Inc. has announced the successful closing of its underwritten offering, raising about $96.9 million through the sale of nearly 25 million shares of common stock. The funds from this offering will be allocated towards research, development, and general corporate expenses. The offering included participation from a range of investors, indicating a strong interest in the company's developments, particularly its antibody therapy for treating hyperinsulinism. Additionally, a private placement to further raise capital is expected to close shortly.
Read more →RZLT▲ +27.7%on this newsshared move
Rezolute Announces Positive Recommendation After Independent Interim Analysis of Phase 3 sunRIZE Study of Ersodetug in Congenital Hyperinsulinism ("HI") Independent Data Monitoring Committee (the "DMC") recommends contin
Rezolute, Inc. announced that the Independent Data Monitoring Committee (DMC) has recommended continuing the Phase 3 sunRIZE study of ersodetug for congenital hyperinsulinism without the need to increase the sample size. The study is on track for completion of enrollment by May 2025, with topline results expected in December 2025. Rezolute's CMO expressed confidence in the treatment's efficacy based on previous studies and real-world observations. The study aims to evaluate the safety and efficacy of ersodetug, with enrollment occurring in multiple countries globally.
Read more →RZLT▲ +27.7%on this newsshared move
Rezolute Announces Positive Recommendation After Independent Interim Analysis of Phase 3 sunRIZE Study of Ersodetug in Congenital Hyperinsulinism (“HI”)
Rezolute, Inc. announced a positive recommendation from the Data Monitoring Committee (DMC) to continue the Phase 3 sunRIZE study of ersodetug for congenital hyperinsulinism (HI). The study is on track for enrollment completion by May 2025, with topline results expected in December 2025. The DMC's recommendation supports the study's design and initial assumptions, indicating confidence in the treatment's potential.
Read more →RZLT▲ +27.7%on this newsshared move
Rezolute Announces Pricing of Offering of $90 Million of Common Stock and Pre-Funded Warrants NEW YORK-(BUSINESS WIRE)
Rezolute, Inc. has announced the pricing of a $90 million underwritten offering of its common stock and pre-funded warrants. The offering, priced at $3.25 per share, includes participation from notable investors and is expected to close around April 24, 2025. The proceeds from the offering will be utilized for research and development, along with general corporate expenses. This follows Rezolute's commitment to develop therapies for serious rare diseases, particularly hypoglycemia caused by hyperinsulinism.
Read more →RZLT▼ -5.5%on this news
Rezolute Announces Appointment of Rare Disease Commercial Leader Erik Harris to its Board of Directors
Rezolute, Inc. has appointed Erik Harris, Chief Commercial Officer at Ultragenyx, to its Board of Directors. With over two decades of experience in the biopharmaceutical industry, Harris is expected to provide strategic insights that will aid in advancing the company's lead therapies through clinical development and commercialization. Rezolute is focused on developing treatments for rare diseases, specifically for hyperinsulinism, where its product ersodetug has shown promising results in trials. This appointment comes as the company prepares for the next phase of its development.
Read more →RZLTRezolute Reports Second Quarter Fiscal 2025 Financial Results and Provides Business Update
Rezolute, Inc. reported its financial results for Q2 of fiscal 2025, highlighting significant progress with its drug ersodetug, which has received Breakthrough Therapy Designation from the FDA. The company is advancing Phase 3 trials for congenital and tumor hyperinsulinism, with enrollment expected to start in Q2 2025. Despite a net loss increase, the company remains optimistic about its pipeline.
Read more →RZLTRezolute Reports Second Quarter Fiscal 2025 Financial Results and Provides Business Update Ersodetug, a novel, fully human monoclonal antibody for the treatment of hyperinsulinism (HI), receives Breakthrough Therapy Desi
Rezolute, Inc. announced its financial results for the second quarter of fiscal 2025, highlighting significant progress in its clinical trials for Ersodetug, a monoclonal antibody targeting hyperinsulinism. The drug has received both Breakthrough Therapy and Orphan Drug Designation, improving its development prospects. Notably, safety assessments in infant participants were positive, allowing for enrollment in the next trial phase. However, the company also reported a net loss of $15.7 million and decreased cash reserves, indicating financial pressures as it advances its pipeline.
Read more →RZLTRezolute Provides Update on its Phase 3 sunRIZE Study of Ersodetug for the Treatment of Hypoglycemia Due to Congenital Hyperinsulinism
Rezolute, Inc. announced positive outcomes from the open-label arm of its Phase 3 sunRIZE study for ersodetug, aimed at treating congenital hyperinsulinism. The Data Monitoring Committee confirmed the safety of the drug in infants and approved their enrollment in the double-blind portion. The study's enrollment is expected to complete by Q2 2025, with topline results anticipated by late 2025, pending interim analysis outcomes.
Read more →RZLTRezolute Provides Update on its Phase 3 sunRIZE Study of Ersodetug for the Treatment of Hypoglycemia Due to Congenital Hyperinsulinism Open-label arm (infant participants 1 year old) has been recently reviewed by a Data
Rezolute announced positive outcomes from the Data Monitoring Committee's review of the Phase 3 sunRIZE study for ersodetug, aimed at treating congenital hyperinsulinism. The open-label arm has been fully enrolled with eight infant participants showing good safety and pharmacokinetics. Importantly, the DMC approved moving forward with enrolling infants into the double-blind portion of the study. The company anticipates completing enrollment by Q2 2025, with interim analysis results expected soon.
Read more →RZLTRezolute to Participate in the Guggenheim SMID Cap Biotech Conference
Rezolute, Inc. will participate in the Guggenheim SMID Cap Biotech Conference scheduled for February 5-6, 2025, in New York City. During the event, management will hold one-on-one meetings with potential investors, providing an opportunity to discuss the company's progress and focus on developing therapies for rare diseases, particularly hypoglycemia caused by hyperinsulinism. Rezolute's therapy, ersodetug, has shown significant benefits in clinical trials, highlighting the company's commitment to addressing serious unmet medical needs.
Read more →RZLTRezolute Film Transcript Ersodetug is an investigational drug candidate. The FDA has not determined that ersodetug is safe or effective. No indication(s), warnings, precautions, adverse reactions, dosage or administratio
Rezolute is developing ersodetug, an investigational drug candidate for hyperinsulinism. While favorable results have been reported from a single patient's experience, the FDA has not confirmed its safety or effectiveness, and no dosage or administration information has been approved. The company is hopeful about the ongoing Phase 3 clinical trials, which aim to further evaluate the drug's potential impact on patients' lives, as seen in the case of Paula, who experienced significant improvements while using ersodetug.
Read more →RZLTRezolute Receives Breakthrough Therapy Designation from FDA for Ersodetug in the Treatment of Hypoglycemia Due to Congenital Hyperinsulinism
Rezolute, Inc. has received Breakthrough Therapy Designation from the FDA for its drug ersodetug, aimed at treating hypoglycemia due to congenital hyperinsulinism. This designation is based on positive results from the Phase 2b RIZE study, which demonstrated significant improvements in hypoglycemia. The company is focused on completing recruitment for the sunRIZE study and expects topline results later this year.
Read more →RZLTRezolute Receives Breakthrough Therapy Designation from FDA for Ersodetug in the Treatment of Hypoglycemia Due to Congenital Hyperinsulinism Breakthrough Therapy Designation granted based on key positive data from the Ph
Rezolute, Inc. has received Breakthrough Therapy Designation from the FDA for its drug ersodetug, intended for treating hypoglycemia due to congenital hyperinsulinism. This designation emphasizes the treatment's potential to significantly improve clinical outcomes based on positive data from the Phase 2b RIZE study. The company is advancing in its clinical development, with topline results from the sunRIZE study expected later this year. Rezolute is dedicated to developing therapies for rare diseases and aims to address the serious challenges posed by hyperinsulinism.
Read more →RZLTRezolute Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
Rezolute, Inc. announced the issuance of 150,000 shares as an inducement award to its newly appointed Senior Vice President of Global Product Supply, in line with Nasdaq Rule 5635(c)(4). The award, priced at the closing stock price from November 29, 2024, will vest 25% after one year and the remainder monthly over three years. This move signals the company's commitment to strengthening its leadership as it develops treatments for rare diseases such as hypoglycemia due to hyperinsulinism.
Read more →RZLTFDA Grants Orphan Drug Designation to Rezolute’s Ersodetug (RZ358) for the Treatment of Hypoglycemia Due to Tumor Hyperinsulinism
Rezolute, Inc. announced that the FDA has granted Orphan Drug Designation to its drug, ersodetug, for treating hypoglycemia due to tumor hyperinsulinism. This designation recognizes the serious unmet needs of patients and may expedite the drug's development. The Phase 3 trial is expected to start in 2025, and ersodetug has shown promise in real-world applications.
Read more →RZLTRezolute Reports First Quarter Fiscal 2025 Financial Results and Provides Business Update
Rezolute, Inc. reported its financial results for the first quarter of fiscal 2025, highlighting progress in its late-stage clinical trials for ersodetug, a monoclonal antibody for hyperinsulinism. The company anticipates U.S. enrollment for the Phase 3 sunRIZE study to begin in early 2025, with topline results expected in the second half of 2025. Despite a net loss of $15.4 million, Rezolute remains focused on advancing its clinical programs.
Read more →RZLTRezolute Reports First Quarter Fiscal 2025 Financial Results and Provides Business Update Ersodetug, a novel, fully human monoclonal antibody for the treatment of hyperinsulinism (HI), advancing in two late-stage, regist
Rezolute, Inc. reported its financial results for the first quarter of fiscal 2025, indicating a continued focus on its late-stage clinical programs for its monoclonal antibody, ersodetug, aimed at treating hyperinsulinism. The company highlighted progress in recruitment for its Phase 3 sunRIZE study and is set to start a second study for tumor HI in 2025. Despite a rise in operational costs leading to an increased net loss, Rezolute's financial resources remain robust with over $117 million available. The CEO emphasized the critical importance of 2025 for advancing their therapeutic programs.
Read more →RZLTRezolute Reports Fourth Quarter and Full Year Fiscal 2024 Financial Results and Provides Business Update FDA lifts partial clinical holds on ersodetug for the treatment of congenital HI; Phase 3 sunRIZE study to proceed
Rezolute, Inc. has reported its fourth quarter and full year fiscal 2024 financial results, highlighting the lifting of partial clinical holds by the FDA on its investigational drug, ersodetug, designed for treating congenital hyperinsulinism (HI). The company is poised to move forward with the Phase 3 sunRIZE study set to begin participant enrollment in the U.S. in early 2025. Despite a substantial cash reserve of $127.1 million, resulted from net losses rising to $68.5 million, the company indicates strong prospects for ersodetug as a treatment. Anticipations remain high for future studies as they target critical unmet needs in rare diseases.
Read more →RZLTRezolute Reports Fourth Quarter and Full Year Fiscal 2024 Financial Results and Provides Business Update
Rezolute, Inc. reported its fourth quarter and full year fiscal 2024 financial results, highlighting FDA's removal of partial clinical holds on ersodetug for congenital hyperinsulinism. The company anticipates U.S. enrollment in the Phase 3 sunRIZE study to begin in early 2025. Additionally, positive results from a Phase 2 study of RZ402 for diabetic macular edema were announced, demonstrating safety and efficacy.
Read more →RZLT▲ +22.1%on this news
FDA Lifts Partial Clinical Holds on RZ358 for the Treatment of Congenital Hyperinsulinism and Authorizes U.S. Inclusion in Ongoing Phase 3 Study
Rezolute, Inc. announced that the FDA has lifted partial clinical holds on RZ358, enabling the inclusion of U.S. participants in the global Phase 3 sunRIZE study for congenital hyperinsulinism. The company plans to start study activities in the U.S. with enrollment anticipated in early 2025. This development follows the FDA's clearance of a separate Phase 3 study for tumor-associated hyperinsulinism.
Read more →RZLT▲ +22.1%on this news
FDA Lifts Partial Clinical Holds on RZ358 for the Treatment of Congenital Hyperinsulinism and Authorizes U.S. Inclusion in Ongoing Phase 3 Study Commencing study startup activities in the U.S.; participant enrollment ant
Rezolute, Inc. announced that the FDA has lifted partial clinical holds on its treatment RZ358 for congenital hyperinsulinism, enabling the company to proceed with study activities in the U.S. The global Phase 3 study, called sunRIZE, will include U.S. participants starting in early 2025, with topline data expected in the latter half of that year. The lift follows the FDA's conclusion that previously observed liver toxicity in animal studies is strain-specific and not relevant to human subjects. This development is expected to advance Rezolute's dual Phase 3 programs for this rare disease.
Read more →RZLTRezolute Announces FDA Clearance of IND Application for Phase 3 Registrational Study of RZ358 for Treatment of Hypoglycemia Due to Tumor Hyperinsulinism
Rezolute, Inc. has received FDA clearance for its IND application for RZ358, aimed at treating hypoglycemia due to tumor hyperinsulinism. The Phase 3 registrational study will begin patient enrollment in the first half of 2025. The drug has shown positive results in previous treatments and aims to improve the quality of life for affected patients.
Read more →RZLTRezolute Announces FDA Clearance of IND Application for Phase 3 Registrational Study of RZ358 for Treatment of Hypoglycemia Due to Tumor Hyperinsulinism Second rare disease program with RZ358 in Phase 3 development Follo
Rezolute, Inc. has received FDA clearance for the IND application of RZ358, which is set to enter a Phase 3 registrational study aimed at treating hypoglycemia due to tumor hyperinsulinism. The company plans to start patient enrollment in the first half of 2025. This trial builds on prior successful treatments administered under the Expanded Access Program, where patients with tumor hyperinsulinism demonstrated positive responses to ersodetug. The primary aim of the Phase 3 study is to evaluate the efficacy and safety of the drug in managing severe hypoglycemic events in affected individuals.
Read more →RZLT▲ +7.2%on this news
Topline Results: RZ402 - 201 Phase 2 Study in Patients with Diabetic Macular Edema (DME)
The Phase 2 study of RZ402 for patients with Diabetic Macular Edema (DME) yielded positive topline results, highlighting a significant reduction in Central Subthreshold Thickness (CST) compared to placebo. RZ402 was noted for its oral administration, safety profile, and ability to achieve effective drug concentrations, marking it as a promising treatment alternative for DME. The drug showed potential effectiveness for patients with limited responses to existing anti-VEGF therapies, suggesting a new avenue for DME management.
Read more →RZLTRezolute Announces Exercise of Underwriters’ Option to Purchase Additional Shares and Concurrent Private Placement
Rezolute, Inc. announced the exercise of an underwriters' option to purchase additional shares, resulting in approximately $67 million in gross proceeds. This follows their public offering that closed on June 24, 2024. The company also secured a concurrent private placement of 1.5 million shares, further bolstering its funding for developing therapies for rare diseases.
Read more →RZLTRezolute Announces Exercise of Underwriters' Option to Purchase Additional Shares and Concurrent Private Placement Additional $6.7M in funding resulting in approximately $67M in gross proceeds NEW YORK--(BUSINESS WIRE)
Rezolute announced the exercise of an over-allotment option by underwriters to purchase an additional 1,786,589 shares, raising approximately $67 million in gross proceeds. This follows a public offering that closed on June 24, 2024. Concurrently, Rezolute plans a private placement of 1,500,000 shares, also priced at $4.00 per share, indicating continued investor interest. The company is focused on developing therapies for rare diseases and has promising data on its treatment for hyperinsulinism.
Read more →RZLT▲ +7.8%on this newsshared move
Rezolute Announces Closing of Public Offering with Approximately $60M in Gross Proceeds
Rezolute, Inc. has successfully closed a public offering, raising around $60 million in gross proceeds. The company sold 11.25 million shares and pre-funded warrants, with net proceeds directed towards corporate activities and advancing its RZ358 program, which targets tumor hyperinsulinism. This move follows the promising results of RZ358 in treating various forms of hyperinsulinism. The offering involved multiple financial institutions and adheres to regulatory requirements for public offerings.
Read more →RZLT▼ -5.8%on this news· ran to -29% by day 3
Rezolute Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
Rezolute, Inc. has announced a public offering of common stock and pre-funded warrants to raise capital. The offering is underwritten by Jefferies and Cantor, with an option for underwriters to purchase an additional 15% of shares. While the public offering is intended to support the company's development of therapies for rare diseases like hyperinsulinism, it is subject to market conditions and may not proceed as planned. The company emphasizes potential risks surrounding the offering and future performance.
Read more →RZLT▼ -5.8%on this news· ran to -29% by day 3
Rezolute Announces Pricing of Public Offering of $60 Million of Common Stock and Pre-Funded Warrants NEW YORK--(BUSINESS WIRE)
Rezolute, Inc. has announced the pricing of a public offering, aiming to raise $60 million through the sale of 11.25 million shares at $4.00 each and pre-funded warrants. This financial maneuver is positioned to bolster the company's efforts in developing treatments for serious rare diseases, particularly focusing on conditions caused by hyperinsulinism. The offering is expected to close on June 17, 2024, subject to standard conditions. Jefferies and Cantor are leading the deal as book-running managers.
Read more →RZLTRezolute to Participate in the Jefferies Global Healthcare Conference
Rezolute, Inc. will participate in the Jefferies Global Healthcare Conference on June 6, 2024, where CEO Nevan Charles Elam will engage in a fireside chat. The event will be live-streamed and subsequently archived for 90 days. Additionally, Rezolute management will hold one-on-one meetings with investors throughout the conference, highlighting their commitment to advancing treatment for metabolic and rare diseases.
Read more →RZLT▲ +6.8%on this news· ran to +27% by day 3
Rezolute Reports Positive Topline Results from Phase 2 Proof of Concept Study of RZ402 in Patients with Diabetic Macular Edema (DME) Met primary study endpoints: good safety profile and reduction in central subfield thic
Rezolute, Inc. announced positive topline results from its Phase 2 proof-of-concept study of RZ402 for diabetic macular edema (DME). The study demonstrated a significant reduction in central subfield thickness across all dosage levels, with a good safety profile observed among participants. RZ402 presents a potential non-invasive treatment option, which addresses the prevalent challenges associated with current anti-VEGF injection therapies. The company plans to present further data at an upcoming medical conference.
Read more →RZLT▲ +6.8%on this news· ran to +27% by day 3
Rezolute Reports Positive Topline Results from Phase 2 Proof of Concept Study of RZ402 in Patients with Diabetic Macular Edema (DME)
Rezolute, Inc. announced positive topline results from its Phase 2 study of RZ402 for diabetic macular edema (DME). The study met primary endpoints, showing a significant reduction in central subfield thickness and a favorable safety profile. RZ402 could represent a transformative oral therapy for DME patients, with results indicating potential for early intervention.
Read more →RZLTRezolute Reports Third Quarter Fiscal 2024 Financial Results and Provides Business Update Patient enrollment underway in sunRIZE global Phase 3 clinical study of RZ358 in patients with congenital hyperinsulinism (cHI); t
Rezolute, Inc. reported its financial results for Q3 FY 2024, highlighting the ongoing enrollment in the Phase 3 clinical study of RZ358 for congenital hyperinsulinism. The company is optimistic about upcoming topline results expected in mid-2025 and has noted no toxicology abnormalities in studies conducted. However, Rezolute reported an increase in net loss compared to the prior year, alongside a significant decrease in cash reserves.
Read more →RZLTRezolute Reports Third Quarter Fiscal 2024 Financial Results and Provides Business Update
Rezolute, Inc. reported its financial results for Q3 2024, highlighting ongoing patient enrollment in the Phase 3 sunRIZE study for RZ358 targeting congenital hyperinsulinism. The company has completed a toxicology study showing no abnormalities at high doses. However, it continues to face partial clinical holds from the FDA, impacting its development timelines.
Read more →RZLT▼ -19.2%on this news
Phase 2 RIZE Study Sub-Analyses to be Presented at the 2024 Pediatric Endocrine Society Annual Meeting
Rezolute, Inc. announced that a poster detailing sub-analyses from its Phase 2 RIZE study will be presented at the 2024 Pediatric Endocrine Society Annual Meeting. The study focuses on the treatment of congenital hyperinsulinism (HI) using RZ358, showcasing a reduction in overnight hypoglycemia in pediatric patients. Initial results indicated significant improvements in overall hypoglycemia management, reflecting the treatment's potential. A Phase 3 study is currently in progress to further evaluate RZ358's efficacy.
Read more →RZLTRezolute Reports Validation of the Potential Use of RZ358 for Treatment of Non-Islet Cell Tumor Hypoglycemia (NICTH)
Rezolute, Inc. has reported promising results from a preclinical study validating RZ358's potential application in treating non-islet cell tumor hypoglycemia (NICTH). The study demonstrated RZ358's ability to block insulin receptor activation mediated by insulin-like growth factor-2 (IGF-2), suggesting broad therapeutic utility in various forms of hyperinsulinism. The company is also planning to engage in a registrational study with the FDA to explore treatment possibilities for both NICTH and islet cell tumor hypoglycemia (ICTH), potentially expanding the market significantly. Rezolute's ongoing Phase 3 trial for RZ358 in congenital hyperinsulinism adds to its therapeutic relevance in serious metabolic disorders.
Read more →RZLTRezolute Reports Second Quarter Fiscal 2024 Results and Provides Business Update
Rezolute, Inc. reported its Q2 fiscal 2024 results, highlighting progress in its clinical pipeline. The company initiated a Phase 3 study for RZ358 in congenital hyperinsulinism, with topline results expected in mid-2025. Additionally, RZ358 has shown promise in treating tumor-associated hyperinsulinism, and the company is addressing ongoing clinical holds with the FDA. Rezolute also completed enrollment for its Phase 2 study of RZ402 in diabetic macular edema.
Read more →RZLTRezolute Reports Second Quarter Fiscal 2024 Results and Provides Business Update Phase 3 clinical study of RZ358 underway in patients with congenital hyperinsulinism (cHI); topline results expected in mid-2025 Benefit sh
Rezolute, Inc. reported its financial results for the second quarter of fiscal 2024 and provided updates on its clinical development programs. The company has commenced a pivotal Phase 3 clinical study, sunRIZE, for RZ358 in patients with congenital hyperinsulinism, and has noted favorable individual patient outcomes from an Expanded Access Program for the same drug. Additionally, enrollment in the Phase 2 study of RZ402 for diabetic macular edema has been completed, with topline data expected in the upcoming quarter. Despite these advancements, Rezolute continues to experience net losses and an increasing accumulated deficit.
Read more →RZLT▲ +6.4%on this news
Rezolute Expands Leadership Team with Appointment of Daron Evans, MS, MBA, as Chief Financial Officer
Rezolute, Inc. has appointed Daron Evans as its new Chief Financial Officer, a move aimed at strengthening its leadership team as the company embarks on important clinical trials. Daron Evans brings over 15 years of experience in financial operations and biotechnology, previously leading multiple life science companies. This strategic appointment coincides with Rezolute's Phase 3 study for RZ358 and anticipations for topline data from another trial involving RZ402. The company continues to focus on developing transformative therapies for rare and metabolic diseases.
Read more →RZLTRezolute Receives Innovation Passport Designation from the U.K. Innovative Licensing and Access Pathway Steering Group for RZ358 in the Treatment of Hypoglycemia Due to Congenital Hyperinsulinism
Rezolute, Inc. has received Innovation Passport designation from the U.K. Medicines and Healthcare products Regulatory Agency for RZ358, a treatment aimed at congenital hyperinsulinism. This designation underscores the unmet medical need and the potential benefits highlighted in the Phase 2 RIZE study, which demonstrated significant improvements in hypoglycemia events. The Innovation Passport facilitates expedited discussions for market access through the Innovative Licensing and Access Pathway. Rezolute aims to work closely with healthcare regulators to make this therapy available for patients in need.
Read more →RZLTRezolute Initiates Phase 3 Clinical Study for RZ358 in Congenital Hyperinsulinism
Rezolute, Inc. has initiated the sunRIZE Phase 3 clinical study for RZ358, targeting congenital hyperinsulinism. This move follows the success of the Phase 2 RIZE study, which showcased RZ358's effectiveness and safety in treating this condition. The new study aims to evaluate RZ358's efficacy in controlling hypoglycemia among patients aged 3 months to 45 years. The study benefits from recent approvals and aims to address the significant unmet needs of patients affected by congenital hyperinsulinism, particularly since current treatments are often ineffective or have severe side effects.
Read more →RZLT▲ +8.4%on this newsshared move
Rezolute Completes Enrollment of its Phase 2 Study in Diabetic Macular Edema ("DME") Plans to report topline data mid-second quarter 2024 Redwood City, Calif.
Rezolute, Inc. has completed enrollment for its Phase 2 study of RZ402 in diabetic macular edema (DME). The clinical trial aims to evaluate the efficacy, safety, and pharmacokinetics of RZ402 as a potential oral therapy. Final study enrollment totalled approximately 95 participants. Topline results are now expected in mid-second quarter 2024 instead of the previously anticipated end of first quarter 2024.
Read more →RZLT▲ +8.4%on this newsshared move
Rezolute Completes Enrollment of its Phase 2 Study in Diabetic Macular Edema (“DME”)
Rezolute, Inc. has completed enrollment in its Phase 2 study for RZ402, a potential oral therapy for diabetic macular edema (DME). The trial aims to evaluate the safety and efficacy of RZ402, with topline results expected in mid-second quarter 2024. The study has enrolled approximately 95 participants, reflecting strong interest in new treatment options for DME.
Read more →RZLTRezolute to Participate in BTIG’s 3rd Annual Ophthalmology Day
Rezolute, Inc. (Nasdaq: RZLT) will participate in BTIG's 3rd Annual Ophthalmology Day on November 27th, where they will discuss their investigational drug, RZ402. This oral plasma kallikrein inhibitor is aimed at treating diabetic macular edema. The event includes a Q&A session and investor meetings throughout the day, emphasizing Rezolute's commitment to advancing novel therapies for serious diseases. The company's approach integrates patient voices in the drug development process, aiming for significant improvements in treatment efficacy and patient experiences.
Read more →RZLT▲ +12.2%on this news
Rezolute Reports First Quarter Fiscal 2024 Results Redwood City, Calif.
Rezolute, Inc. reported its financial results for the first quarter of fiscal 2024, highlighting significant developments in its clinical programs. The company has received PRIME eligibility from the European Medicines Agency for RZ358, poised to begin a Phase 3 study targeting congenital hyperinsulinism. Concurrently, enrollment is nearing completion for the Phase 2 study of RZ402 aimed at diabetic macular edema, with results expected before year-end. However, the results also show an increased net loss and rising operating expenses compared to the previous year.
Read more →RZLT▲ +12.2%on this news
Rezolute Reports First Quarter Fiscal 2024 Results
Rezolute, Inc. reported its financial results for the first quarter of fiscal 2024, highlighting advancements in its clinical studies. The company is set to initiate a Phase 3 study for RZ358 targeting congenital hyperinsulinism and is nearing completion of enrollment for its Phase 2 study of RZ402 for diabetic macular edema. Despite a rise in net loss and increased expenses, the company remains focused on its innovative therapies.
Read more →RZLT▲ +6.5%on this news
Rezolute Receives Priority Medicines (PRIME) Eligibility from European Medicines Agency for Enhanced Regulatory Support of RZ358 in Congenital Hyperinsulinism PRIME eligibility granted based on key positive data from the
Rezolute, Inc. has announced that RZ358 has received Priority Medicines (PRIME) eligibility from the European Medicines Agency for the treatment of congenital hyperinsulinism. This designation was awarded based on positive data from the Phase 2b study (RIZE) and highlights the significant unmet medical need in this area, as there are currently no authorized therapies available. Rezolute plans to initiate a Phase 3 trial for RZ358 in the near future, which is expected to potentially improve patient outcomes significantly.
Read more →RZLT▲ +6.5%on this news
Rezolute Receives Priority Medicines (PRIME) Eligibility from European Medicines Agency for Enhanced Regulatory Support of RZ358 in Congenital Hyperinsulinism
Rezolute, Inc. announced that the European Medicines Agency granted PRIME eligibility to RZ358 for treating congenital hyperinsulinism, highlighting the unmet medical need. This designation is based on positive data from the Phase 2b RIZE study, which showed significant improvements in hypoglycemia events. Rezolute plans to initiate a Phase 3 study for RZ358 soon.
Read more →RZLT▼ -6%on this news
Rezolute Announces Further Evidence of RZ358's Efficacy in Tumor-Mediated Hyperinsulinism Redwood City, Calif.
Rezolute, Inc. announced positive developments regarding RZ358, a treatment for refractory hypoglycemia due to tumor-mediated hyperinsulinism. The results from an expanded access program have shown that RZ358 effectively resolved hypoglycemia in patients with different tumor types. The company highlighted the potential of RZ358 as a universal therapy for various causes of hyperinsulinism. Additionally, Rezolute is preparing to initiate a Phase 3 trial, further advancing their clinical efforts for this treatment.
Read more →RZLT▼ -6%on this news
Rezolute Announces Further Evidence of RZ358’s Efficacy in Tumor-Mediated Hyperinsulinism
Rezolute, Inc. announced positive results from administering RZ358 to a patient with refractory hypoglycemia caused by tumor-mediated hyperinsulinism. The treatment resolved the patient's hypoglycemia, allowing her to continue cancer therapy. This follows previous success with RZ358 in another patient with metastatic insulinoma. The company plans to further develop RZ358 for various hyperinsulinism conditions.
Read more →RZLTRezolute Reports Full Year Fiscal 2023 Results and Highlights Company Progress
Rezolute, Inc. reported its fiscal 2023 results, highlighting the upcoming initiation of the Phase 3 sunRIZE study for RZ358 aimed at treating congenital hyperinsulinism. The company anticipates results from its Phase 2 study of RZ402 for diabetic macular edema in early 2024. Despite a net loss increase, Rezolute remains committed to advancing its clinical programs.
Read more →RZLTRezolute Reports Full Year Fiscal 2023 Results and Highlights Company Progress Planning to initiate Phase 3 Study for RZ358 ("sunRIZE study") in the fourth quarter of 2023
Rezolute, Inc. reported its financial results for the full fiscal year 2023, highlighting plans to initiate the Phase 3 study called sunRIZE for RZ358 in the fourth quarter. The CEO expressed optimism about reaching important milestones, including the anticipated results from a Phase 2 study of RZ402 in early 2024. Despite the positive developments, the company faced challenges, including a significant financial loss and a decrease in cash reserves compared to the previous year. Rezolute continues its mission to develop therapies for debilitating metabolic diseases.
Read more →RZLTRezolute to Participate in Upcoming Investor Conferences in September
Rezolute, Inc. announced that CEO Nevan Charles Elam will participate in two upcoming investor conferences in New York this September. The events include the H.C. Wainwright 25th Annual Global Investment Conference and the Cantor Fitzgerald Global Healthcare Conference, both offering presentations that showcase the company's developments. Live webcasts will be available for viewing, allowing wider access for potential investors and stakeholders.
Read more →RZLTRezolute to Initiate a Pivotal Phase 3 Study of RZ358 in Participants 3 Months of Age and Older with Congenital Hyperinsulinism Study to be initiated in Europe and other ex-US geographies in Q4 2023, with topline results
Rezolute, Inc. plans to initiate a pivotal Phase 3 study for RZ358, targeting congenital hyperinsulinism in patients aged 3 months and older. The study, named sunRIZE, is set to begin in Q4 2023 in Europe and other regions outside the US, with topline results anticipated in the first half of 2025. While the company has secured alignment with European regulators, it faces challenges in the US due to FDA restrictions on age and dosing for the drug. Rezolute is exploring nonclinical studies to address these regulatory concerns as they advance the trial in other markets.
Read more →RZLTRezolute Reports Third Quarter Fiscal 2023 Results and Highlights Company Progress The Company is poised to commence Phase 3 for RZ358 in the third quarter of calendar year 2023
Rezolute, Inc. has reported its financial results for Q3 of fiscal 2023 and highlighted ongoing advancements in its clinical pipeline. The company is preparing to initiate a Phase 3 study for RZ358 and has begun patient enrollment for its Phase 2 study of RZ402. The leadership expressed optimism about the support from key opinion leaders in ophthalmology and the potential to change treatment paradigms. However, the firm also recorded a significant net loss, raising concerns regarding its financial health moving forward.
Read more →RZLT▼ -5.3%on this news
Rezolute KOL Event Highlights Significant Unmet Medical Need in Diabetic Macular Edema
Rezolute, Inc. hosted a virtual KOL event discussing the unmet medical need in Diabetic Macular Edema (DME) and the potential of its oral plasma kallikrein inhibitor, RZ402. Experts highlighted the burdens of current DME treatments and the promising benefits of RZ402 as a first-line monotherapy. The Phase 2 study for RZ402 has been initiated, aiming to evaluate its safety and efficacy in DME patients. Results from the Phase 1b study indicated that RZ402 was safe and well-tolerated, signaling a potential shift in the treatment paradigm for this condition.
Read more →RZLT▲ +7.4%on this news
Rezolute to Highlight RZ402 Phase 2 Clinical Program with Leading Clinical Expert
Rezolute, Inc. is set to highlight its RZ402 Phase 2 clinical program focusing on diabetic macular edema during a virtual event on March 22, 2023. The program features insights from Dr. Robert Bhisitkul, a leading clinical expert. RZ402, an oral plasma kallikrein inhibitor, aims to provide a new treatment option for this significant vision-threatening condition, which currently relies on frequent invasive treatments that are not always effective. Results from previous studies show promising safety and efficacy for RZ402, making it a noteworthy development in DME therapy.
Read more →RZLTRezolute Reports Second Quarter Fiscal 2023 Results and Highlights Company Progress Initiated Phase 2 proof-of-concept study of RZ402 Anticipate initiation of global Phase 3 clinical study for RZ358 in mid 2023
Rezolute, Inc. reported its financial results for the second quarter of fiscal 2023, highlighting the initiation of a Phase 2 proof-of-concept study for RZ402 targeting diabetic macular edema. The company anticipates launching a global Phase 3 study for RZ358, aimed at treating congenital hyperinsulinism, in mid-2023. While the company is making progress in advancing its drug pipeline, it continues to face financial challenges, with reported substantial losses in recent quarters. These developments reflect Rezolute's commitment to transforming treatment options for patients with metabolic diseases.
Read more →RZLTRezolute Announces Initiation of a Phase 2 Study of RZ402 in Patients with Diabetic Macular Edema RZ402 is an oral therapy being developed as a potential alternative to invasive and suboptimal injections into the eye
Rezolute Announces Initiation of a Phase 2 Study of RZ402 in Patients with Diabetic Macular Edema RZ402 is an oral therapy being developed as a potential alternative to invasive and suboptimal injections into the eye REDWOOD CITY, Calif., Dec. 15, 2022 (GLOBE NEWSWIRE) -- Re
Read more →RZLTRezolute Reports First Quarter Fiscal 2023 Results and Highlights Company Progress Phase 2 proof-of-concept study of RZ402 expected to be initiated by the end of this year
Rezolute Reports First Quarter Fiscal 2023 Results and Highlights Company Progress Phase 2 proof-of-concept study of RZ402 expected to be initiated by the end of this year CITY, Calif., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharm
Read more →RZLTRezolute to Present at the Jefferies London Healthcare Conference
REDWOOD CITY, Calif., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company dedicated to developing transformative therapies with the potential to shift the treatment paradigms of devastating metabolic diseases, today announce
Read more →RZLTRezolute Announces Presentation at The Retina Society 55th Annual Scientific Meeting
REDWOOD CITY, Calif., Oct. 20, 2022 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company dedicated to developing transformative therapies with the potential to shift the treatment paradigms of devastating metabolic diseases, today announce
Read more →RZLTRezolute Reports Fourth Quarter and Full Year Fiscal 2022 Results and Highlights Company Progress Announced a $130 million registered direct offering and concurrent private placement priced at-the-market Late-breaking or
Rezolute Reports Fourth Quarter and Full Year Fiscal 2022 Results and Highlights Company Progress Announced a $130 million registered direct offering and concurrent private placement priced at-the-market presentation from Phase 2b RIZE study of RZ358 presented at ESPE 2022 P
Read more →RZLTRezolute Announces Presentation at the 60th Annual ESPE Meeting
Data from Phase 2b RIZE Study in congenital hyperinsulinism will be presented in oral presentation REDWOOD CITY, Calif., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company dedicated to developing transformative therapies
Read more →RZLTRezolute Announces Promotion of Brian Roberts, M.D. to Chief Medical Officer
REDWOOD CITY, Calif., June 01, 2022 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company dedicated to developing transformative therapies with the potential to disrupt current treatment paradigms for devastating metabolic diseases, today a
Read more →RZLTRezolute Reports Third Quarter Fiscal 2022 Financial Results and Highlights Company Progress Announced a $130 million registered direct offering and concurrent private placement Positive topline results from Phase 2b RIZ
Third Quarter Fiscal 2022 Financial Results and Highlights Company Progress million registered direct offering and concurrent private placement topline results from Phase 2b RIZE study of RZ358 exceeded expectations and demonstrated highly significant reduction in hypoglycemia
Read more →RZLTRezolute, Inc. Announces Closing of Registered Direct Offering
Rezolute, Inc. Announces Closing of Registered CITY, Calif., May 4, 2022 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company dedicated to developing transformative therapies with the potential to disrupt current treatment paradigms for
Read more →RZLTRezolute to Host Corporate Update Call on May 4, 2022
REDWOOD CITY, Calif., May 04, 2022 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company dedicated to developing transformative therapies with the potential to disrupt current treatment paradigms for devastating metabolic diseases, today an
Read more →RZLTRezolute, Inc. Announces Aggregate $130 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market
Rezolute, Inc. Announces Aggregate $130 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market REDWOOD CITY, Calif., May 1, 2022 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company dedicated to develo
Read more →RZLTRezolute Announces Positive Data from its Phase 2b (RIZE) Study of RZ358 in Patients with Congenital Hyperinsulinism
Highly significant ~75% reduction in hypoglycemia events at anticipated therapeutic doses ≥50% improvement in hypoglycemia in 100% of patients in high-dose cohort, with no adverse drug reactions or clinically significant hyperglycemia Study exceeded expectations for correction
Read more →RZLT▼ -8.7%on this news
Rezolute Joins the Rare Disease Company Coalition Rezolute joins group aimed at helping advance timely access to life-saving therapies for those impacted by rare diseases
Rezolute Joins the Rare Disease Company Coalition joins group aimed at helping advance timely access to life-saving therapies for those impacted by rare diseases REDWOOD CITY, Calif., March 29, 2022 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmac
Read more →RZLT▼ -8.7%on this news
Rezolute Joins the Rare Disease Company Coalition
REDWOOD CITY, Calif., March 29, 2022 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company dedicated to developing transformative therapies with the potential to disrupt current treatment paradigms for devastating metabolic diseases, today
Read more →RZLT▲ +7.3%on this news
Rezolute Announces Positive Results from the Phase 2b RIZE Study of RZ358 in Congenital Hyperinsulinism --The RIZE study demonstrated highly significant improvements in hypoglycemia and good safety and tolerability Resul
Rezolute Announces Positive Results from the Phase 2b RIZE Study of RZ358 in Congenital Hyperinsulinism --The RIZE study demonstrated highly significant improvements in hypoglycemia and good safety and tolerability Results to be presented in an oral presentation at a medica
Read more →RZLT▼ -6.2%on this news· ran to -43% by day 3
Rezolute Announces Positive Study Results for RZ402, an oral PKI being developed for DME Phase 2 proof-of-concept study anticipated in 2H 2022
Rezolute Announces Positive Study Results for RZ402, an oral PKI being developed for DME Phase 2 proof-of-concept study anticipated in 2H REDWOOD CITY, Calif., Feb. 22, 2022 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company developi
Read more →RZLTRezolute Reports Second Quarter Fiscal 2022 Financial Results and Highlights Company Progress Topline results from RZ358 Phase 2b and RZ402 Phase 1b studies expected before the end of Q1 2022
Rezolute Reports Second Quarter Fiscal 2022 Financial Results and Highlights Company Progress Topline results from RZ358 Phase 2b and RZ402 Phase 1b studies expected before the end of Q1 2022 REDWOOD CITY, Calif., February 9, 2022 (GLOBE NEWSWIRE) - Rezolute, Inc. (Nasdaq: R
Read more →RZLTRezolute Reports First Quarter Fiscal 2022 Financial Results and Highlights Recent Company Progress
Rezolute Reports First Quarter Fiscal 2022 Financial Results and Highlights Recent Company Progress REDWOOD CITY, Calif., November 12, 2021 (GLOBE NEWSWIRE) - Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company developing transformative therapies for met
Read more →RZLTABSTRACT FOR THE 2021 ASRS MEETING Title: A Phase 1 Single Dose Study of RZ402: a Novel Orally Administered Plasma Kallikrein Inhibitor to Target Diabetic Macular Edema Presenters: Robert Bhisitkul, MD, PhD 1 , Quan Dong
ABSTRACT FOR THE 2021 ASRS MEETING A Phase 1 Single Dose Study of RZ402: a Novel Orally Administered Plasma Kallikrein Inhibitor to Target Diabetic Macular Edema Robert Bhisitkul, MD, PhD1, Quan Dong Nguyen, MD, MSc2, Brian Roberts, MD3, Rajat Agrawal, MD, MS3 The plasma kal
Read more →RZLT▼ -14.2%on this news
Rezolute Announces Pricing of Public Offering of $55 million of Common Stock and Pre-Funded Warrants, and Concurrent Registered Direct Offering
REDWOOD CITY, Calif., Oct. 13, 2021 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a clinical-stage biopharmaceutical company developing transformative therapies for metabolic diseases associated with chronic glucose imbalance, today announced th
Read more →RZLTRezolute Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants, and a Concurrent Registered Direct Offering
Rezolute Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants, and a Concurrent Registered Direct Offering REDWOOD CITY, Calif., October 12, 2021 (GLOBE NEWSWIRE) - Rezolute, Inc. (Nasdaq: RZLT) ("Rezolute" or the "Company"), a clinical-stage biopharmace
Read more →RZLTRezolute Presents Results from Two-Week Natural History Study in Congenital Hyperinsulinism Patients on Standard of Care Therapies at ESPE 2021 Continuous glucose monitoring reveals undertreated hypoglycemia in patients
Rezolute Presents Results from Two-Week Natural History Study in Congenital Hyperinsulinism Patients on Standard of Care Therapies at ESPE 2021 Continuous glucose monitoring reveals undertreated hypoglycemia in patients with congenital hyperinsulinism RZ358, a monoclonal anti
Read more →RZLTRezolute Reports Fourth Quarter and Full Year Fiscal 2021 Financial Results and Highlights Recent Company Progress
Rezolute Reports Fourth Quarter and Full Year Fiscal 2021 Financial Results and Highlights Recent Company Progress REDWOOD CITY, Calif., September 15, 2021 (GLOBE NEWSWIRE) - Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company developing transformative t
Read more →RZLTRezolute Announces Initiation of Dosing in the Second Cohort of its Phase 2b Trial of RZ358 for Congenital Hyperinsulinism Tracking to Announce Top line data in Q1 2022
Rezolute Announces Initiation of Dosing in the Second Cohort of its Phase 2b Trial of RZ358 for Tracking to Announce Top line data in Q1 REDWOOD CITY, CA, September 9, 2021 (GLOBE NEWSWIRE) - Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company developing
Read more →RZLT▲ +5.4%on this news· ran to +16% by day 3shared move
Rezolute to Participate in Upcoming Virtual Healthcare Conferences
REDWOOD CITY, Calif., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company developing transformative therapies for metabolic diseases related to chronic glucose imbalance, today announced that Nevan Charles Elam, CEO and Fou
Read more →RZLT▲ +6.4%on this news
Rezolute Announces initiation of multiple-ascending dose study of RZ402, Rezolute's oral PKI for treatment of
Rezolute Announces initiation of multiple-ascending dose study of RZ402, Rezolute's oral PKI for treatment of DME REDWOOD CITY, Calif., August 10, 2021 (GLOBE NEWSWIRE) - Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company developing transformative ther
Read more →RZLTRezolute Added to Russell Microcap Index
Rezolute Added to Russell Microcap CITY, Calif., June 28, 2021 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company developing transformative therapies for metabolic diseases related to chronic glucose imbalance, has been added to the Ru
Read more →RZLTRezolute Expands Leadership Team with the Appointment of Davelyn Hood, MD as Director, Scientific and Patient Affairs
REDWOOD CITY, Calif., May 20, 2021 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company developing transformative therapies for metabolic diseases associated with chronic glucose imbalance, today announced the addition of Davelyn Hood, MD,
Read more →RZLTRezolute Appoints Leading Ophthalmology Expert, Quan Dong Nguyen, MD, MSc, FAAO, FARVO, to Scientific Advisory Board
REDWOOD CITY, Calif., May 18, 2021 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company developing novel therapies for diseases related to chronic glucose imbalance, today announced the addition of Quan Dong Nguyen, MD, MSc, FAAO, FARVO to
Read more →RZLTRezolute to Present at the Oppenheimer Rare and Orphan Disease Summit
REDWOOD CITY, Calif., May 17, 2021 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company developing novel therapies for diseases caused by chronic glucose imbalance, today announced that management will present at the Oppenheimer Rare and O
Read more →RZLTRezolute Reports Third Quarter Fiscal 2021 Financial Results and Highlights Recent Company Progress
Rezolute Reports Third Quarter Fiscal 2021 Financial Results and Highlights Recent Company Progress CITY, Calif., May 17, 2021 (GLOBE NEWSWIRE) - Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company developing transformative therapies for metabolic disease
Read more →RZLTRezolute Announces Positive RZ402 Study Results Demonstrating Potential for Once Daily Dosing of an Oral Plasma Kallikrein Inhibitor for Diabetic Macular Edema Results allow the Company to advance development, including
Rezolute Announces Positive RZ402 Study Results Demonstrating Potential for Once Daily Dosing of an Oral Plasma Kallikrein Inhibitor for Diabetic Macular Edema Results allow the Company to advance development, including planning for its multiple-ascending dose clinical study.
Read more →RZLTRezolute Announces $30 Million Debt Financing Agreement with SLR Capital Partners
Rezolute Announces $30 Million Debt Financing SLR Capital Partners REDWOOD CITY, Calif., April 19, 2021 (GLOBE NEWSWIRE) -- Rezolute, Inc. ("Rezolute" or "the Company") (Nasdaq: RZLT), a clinical stage biopharmaceutical company dedicated to advancing targeted therapies for ra
Read more →RZLTRezolute Presents Data on RZ358 in Post-Gastric Bypass Hypoglycemia at ENDO 2021
REDWOOD CITY, Calif., March 22, 2021 (GLOBE NEWSWIRE) -- Rezolute, Inc. (“Rezolute” or “the Company”) (Nasdaq: RZLT) today presented positive results of a Phase 2a study of RZ358 in patients with post-gastric bypass hypoglycemia (PGBH), as well as results of a pharmacologic model
Read more →RZLTRezolute Strengthens Board of Directors with Key Appointments of Leading Rare Disease Experts
REDWOOD CITY, Calif., March 08, 2021 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), today announced the appointments of Vlad Hogenhuis, M.D., MBA, and Nerissa C. Kreher, M.D., M.S., MBA to its Board of Directors. “We are delighted to welcome rare disease experts Dr. Hogenhui
Read more →RZLTRezolute to Participate in Upcoming Investor Conferences in March
REDWOOD CITY, Calif., March 02, 2021 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), today announced that Nevan Charles Elam, the Company’s CEO and Founder, will be presenting at the following upcoming investor conferences: Cowen 41 st Annual Health Care Conference (Virtual)
Read more →RZLTRezolute Reports Second Quarter Fiscal 2021 Financial Results
Rezolute Reports Second Quarter Fiscal 2021 Financial Results REDWOOD CITY, Calif., February 10, 2021 (GLOBE NEWSWIRE) - Rezolute, Inc. (Nasdaq: RZLT), today announced its financial results for the quarter ended December 31, 2020. Recent Business Highlights Second Quarter Fi
Read more →RZLTRezolute Announces Initiation of Phase 1 Study of RZ402, an Oral Plasma Kallikrein Inhibitor for the Treatment of Diabetic Macular Edema
RZ402 is a plasma kallikrein inhibitor being investigated as a potential once-daily, oral therapy for DME Trial initiation marks expansion of the Company’s pipeline to a second clinical-stage program, reinforcing its commitment to advancing novel therapies for patients with seri
Read more →RZLTRezolute Announces Change of Transfer Agent
REDWOOD CITY, Calif., Dec. 28, 2020 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq:RZLT), focused on advancing therapies for rare, metabolic and life-threatening diseases, announced today the appointment of IssuerDirect as the Company’s registrar and transfer agent and shareholder su
Read more →RZLTFDA CLEARS REZOLUTE'S IND APPLICATION FOR RZ402 RZ402
CLEARS REZOLUTE'S IND APPLICATION FOR RZ402 IS AN ORALLY AVAILABLE PLASMA KALLIKREIN INHIBITOR IN DEVELOPMENT FOR THE TREATMENT OF DIABETIC MACULAR EDEMA REDWOOD CITY, Calif., Dec. 03, 2020 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq:RZLT), focused on advancing therapies for ra
Read more →RZLTRezolute to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference
REDWOOD CITY, Calif., Nov. 19, 2020 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq:RZLT), a clinical stage biopharmaceutical company dedicated to advancing therapies for rare, metabolic and life-threatening diseases, announced today that Nevan Charles Elam, the Company’s CEO and foun
Read more →RZLTRezolute Announces Uplisting to the Nasdaq Capital Market Trading expected to begin
Rezolute Announces Uplisting to the Nasdaq Trading expected to begin November 9, REDWOOD CITY, California, November 5 , 2020 (GLOBE NEWSWIRE) - Rezolute, Inc. (OCTQB:RZLTD), a clinical stage biopharmaceutical company dedicated to advancing therapies for rare, metabolic and li
Read more →RZLTRezolute Announces Uplisting to the Nasdaq Capital Market
REDWOOD CITY, Calif., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Rezolute, Inc. (OCTQB:RZLTD), a clinical stage biopharmaceutical company dedicated to advancing therapies for rare, metabolic and life-threatening diseases, announced today that the Company’s common shares have been approved
Read more →RZLTRezolute Announces $41 Million Private Placement with Leading Investment Firms and Prepares to Imminently Up-list to Nasdaq -- Financing led by CAM Capital with Federated Hermes Kaufmann, Surveyor Capital, and BVF Partne
Rezolute Announces $41 Million Private Placement with Leading Investment Firms and Prepares to Imminently Up-list to Nasdaq -- Financing led by CAM Capital with Federated Hermes Kaufmann, Surveyor Capital, and BVF Partners participating - REDWOOD CITY, Calif., October 9, 2020
Read more →RZLTRezolute, Inc. Welcomes Pharmaceutical Industry Leader Philippe Fauchet to its Board of Directors
Rezolute, Inc. Welcomes Pharmaceutical Industry Leader Philippe Fauchet to its Board of Directors REDWOOD CITY, California, September 10, 2020 (GLOBE NEWSWIRE) - Rezolute, Inc. ("Rezolute" or "the Company") (OCTQB:RZLT), announced today that the Company has appointed veteran
Read more →RZLTRezolute, Inc. Provides Updates in the Context of the COVID-19 Pandemic: Announces Resumption and US-Expansion of its Phase 2b Study in Congenital Hyperinsulinism
REDWOOD CITY, California, July 27, 2020 (GLOBE NEWSWIRE) -- Rezolute, Inc. (“Rezolute” or “the Company”) (OTCQB:RZLT), today provided an update on the status of the Company’s clinical programs in the context of the global COVID-19 pandemic (“Pandemic”), including its Phase 2b stu
Read more →RZLTRezolute Announces Publication of RZ402 Data in Diabetic Macular Edema (DME) in Investigative Ophthalmology & Visual Science
REDWOOD CITY, Calif., June 15, 2020 (GLOBE NEWSWIRE) -- Rezolute, Inc. (“Rezolute” or “the Company”) (OCTQB:RZLT), announced that the company’s abstract accepted to the virtual Association for Research in Vision and Ophthalmology (ARVO) 2020 meeting, titled “Nonclinical safety an
Read more →RZLTRezolute Receives Rare Pediatric Disease Designation for RZ358, Phase 2b Candidate for the Treatment of Congenital Hyperinsulinism, Enabling Eligibility for Priority Review Voucher
REDWOOD CITY, Calif., June 10, 2020 (GLOBE NEWSWIRE) -- Rezolute, Inc. (“Rezolute” or “the Company”) (OCTQB:RZLT), today announced that the company has received rare pediatric disease designation (RPD) from the Food and Drug Administration (FDA) for RZ358, a potential treatment f
Read more →RZLTRezolute Presents RZ358 Clinical Data-Validated Model of the Pharmacokinetics and Glycemic Response in Congenital Hyperinsulinism at Pediatric Endocrine Society 2020 Annual Meeting
REDWOOD CITY, Calif., June 01, 2020 (GLOBE NEWSWIRE) -- Rezolute, Inc. (“Rezolute” or “the Company”) (OCTQB:RZLT) recently announced that it has validated pharmacokinetic (PK) and pharmacodynamic (PD) models of its lead clinical asset, RZ358. Phase 2a data in adult and pediatric
Read more →RZLTRezolute to Present Clinical Data for RZ358, Lead Candidate in Phase 2b Trial in Congenital Hyperinsulinism at Virtual Pediatric Endocrine Society 2020 Annual Meeting
REDWOOD CITY, Calif., May 28, 2020 (GLOBE NEWSWIRE) -- Rezolute, Inc. (“Rezolute” or “the Company”) (OTCQB:RZLT), today announced an upcoming oral presentation at this year’s Pediatric Endocrine Society meeting, which will be held virtually. Details of the presentation are as fo
Read more →RZLTRezolute, Inc. Announces Updates to Clinical and Business Operations in Response to COVID-19 Pandemic
REDWOOD CITY, Calif., May 14, 2020 (GLOBE NEWSWIRE) -- Rezolute, Inc. (“Rezolute” or “the Company”) (OTCQB:RZLT), today announced an update on the potential impact of the global COVID-19 pandemic on the Company’s clinical and business operations. Through the execution of a busine
Read more →RZLTRezolute Initiates Phase 2b Clinical Trial of Lead Candidate RZ358 in Congenital Hyperinsulinism
REDWOOD CITY, Calif., Feb. 10, 2020 (GLOBE NEWSWIRE) -- Rezolute, Inc. (“Rezolute” or “the Company”) (OTCQB:RZLT), today announced the initiation of the RIZE study (RZ358-606), a Phase 2b clinical trial of its lead candidate, RZ358, in patients with congenital hyperinsulinism (CH
Read more →RZLTRezolute to Present at BIO CEO & Investor Conference 2020
REDWOOD CITY, Calif., Jan. 27, 2020 (GLOBE NEWSWIRE) -- Rezolute, Inc. (“Rezolute” or “the Company”) (OTCQB:RZLT), today announced an upcoming presentation regarding the company’s clinical development in rare disease at the BIO CEO & Investor Conference 2020, to be held in New Yo
Read more →RZLTRezolute, Inc. Announces Top-line Results from Phase 1 Trial Evaluating AB101 in Patients with Diabetes
REDWOOD CITY, Calif., Dec. 18, 2019 (GLOBE NEWSWIRE) -- Rezolute, Inc. (“Rezolute” or “the Company”) (OTCQB:RZLT) today announced top-line results from its Phase 1 trial of AB101, an ultra-long acting basal insulin for potential use in patients with type 1 and type 2 diabetes. AB
Read more →RZLTRezolute Management to Present at 2020 Biotech Showcase Conference
REDWOOD CITY, Calif., Dec. 02, 2019 (GLOBE NEWSWIRE) -- Rezolute, Inc. (“Rezolute” or “Company”) (OTCQB:RZLT), today announced that senior management will present at the 2020 Biotech Showcase Conference in San Francisco on Monday, January 13, 2020 at 9:00 a.m. PT. The audio port
Read more →RZLTRezolute Appoints Nektar Therapeutics COO & CFO to Its Board of Directors
REDWOOD CITY, Calif., Nov. 25, 2019 (GLOBE NEWSWIRE) -- Rezolute, Inc. (“Rezolute” or the “Company”) (OTCQB:RZLT), a biopharmaceutical company specializing in the development of innovative drug therapies for patients with metabolic diseases, announced today the appointment of Gil
Read more →RZLTRezolute Management to Present at 2019 BIO Investor Forum Conference
REDWOOD CITY, Calif., Oct. 11, 2019 (GLOBE NEWSWIRE) -- Rezolute, Inc. (“Rezolute” or “Company”) (OTCQB:RZLT), today announced that senior management will present at the 2019 BIO Investor Forum Conference in San Francisco on Tuesday, October 22, 2019 at 9:00 a.m. PT. The audio p
Read more →RZLTCompany Name: Rezolute, Inc. (RZLT) Event: Canaccord Genuity's 39th Annual Growth Conference Date
Company Name: Rezolute, Inc. (RZLT) Event: Canaccord Genuity's 39th Annual Growth Conference Date: August 8, 2019 <<Michelle Gilson, Analyst, Canaccord Genuity>> Hi, good morning. Thank you so much for joining us and for those of you who just stepped into the room. My name is
Read more →RZLTRezolute Management to Present at 2019 Canaccord Genuity Growth Conference
REDWOOD CITY, Calif., Aug. 05, 2019 (GLOBE NEWSWIRE) -- Rezolute, Inc. (“Rezolute” or “Company”) (OTCQB:RZLT), today announced that senior management will present at the 2019 Canaccord Genuity Growth Conference in Boston on Thursday, August 8, 2019 at 8:30 a.m. ET. The audio por
Read more →RZLTRezolute Completes $45 Million Investment Round with Full Exercise of $20 Million Option
REDWOOD CITY, Calif., July 24, 2019 (GLOBE NEWSWIRE) -- Rezolute, Inc. (“Rezolute”) (OTCQB:RZLT), a clinical stage biopharmaceutical company specializing in the development of transformative therapies targeting metabolic and orphan diseases, announced today that Handok, Inc. (“Ha
Read more →RZLTRezolute Announces $25 Million Private Placement -- Potential Total Investment of $45 Million
REDWOOD CITY, Calif., Jan. 07, 2019 (GLOBE NEWSWIRE) -- Rezolute, Inc. (“Rezolute” or “Company”) (OTCQB:RZLT), a clinical stage biopharmaceutical company specializing in the development of innovative drug therapies for metabolic and orphan diseases, announced today that it has en
Read more →RZLTRezolute Announces Appointment of Keith Vendola as Chief Financial Officer
Rezolute Announces Appointment of Keith Vendola as Chief Financial Officer LOUISVILLE, Colorado, May 16, 2018 - (GLOBE NEWSWIRE) - Rezolute, Inc. ("Rezolute" or the "Company") (OTCQB: RZLT), a clinical stage biopharmaceutical company specializing in the development of innovative
Read more →RZLTRezolute Announces Appointment of Congenital Hyperinsulinism Therapeutic Area Expert, Dr. Christine Ferrara, as Director of Clinical Development
Rezolute Announces Appointment of Congenital Hyperinsulinism Therapeutic Area Expert, Dr. Christine Ferrara, as Director of Clinical Development LOUISVILLE, Colorado, April 9, 2018 - (GLOBE NEWSWIRE) - Rezolute, Inc. ("Rezolute" or the "Company") (OTCQB: RZLT), a clinical stage
Read more →RZLTRezolute Announces Appointment of Hoyoung Huh, M.D., Ph.D. as Vice Chairman of its Board of Directors
LOUISVILLE, Colo., April 04, 2018 (GLOBE NEWSWIRE) -- Rezolute, Inc. (“Rezolute” or the “Company”) (OTCQB:RZLT), a clinical stage biopharmaceutical company specializing in the development of innovative drug therapies for metabolic and orphan diseases, announced today that Hoyoung
Read more →RZLTRezolute, Inc. Announces Appointment of Hoyoung Huh, M.D., Ph.D. as Vice Chairman of its Board of Directors
Rezolute, Inc. Announces Appointment of Hoyoung Huh, M.D., Ph.D. as Vice Chairman of its Board of Directors LOUISVILLE, Colorado, April 4, 2018 - (GLOBE NEWSWIRE) - Rezolute, Inc. ("Rezolute" or the "Company") (OTCQB: RZLT), a clinical stage biopharmaceutical company speciali
Read more →RZLTRezolute, Inc. Announces Close of Convertible Note Financing
Rezolute, Inc. Announces Close of Convertible LOUISVILLE, Colorado, April 3, 2018 - (GLOBE NEWSWIRE) - Rezolute, Inc. ("Rezolute" or the "Company") (OTCQB: RZLT), a clinical stage biopharmaceutical company specializing in the development of innovative drug therapies for metabo
Read more →RZLTRezolute, Inc. Enters into Common Stock Purchase Agreement for Up to $10 Million with Lincoln Park Capital Fund
Rezolute, Inc. Enters into Common Stock Purchase Agreement for Up to $10 Million with Lincoln Park Capital Fund, LLC LOUISVILLE, Colorado, December 26, 2017 - (GLOBE NEWSWIRE) - Rezolute, Inc. ("Rezolute" or the "Company") (OTCQB: RZLT), a clinical stage biopharmaceutical com
Read more →RZLTAntriaBio Announces Exclusive License Agreement for a Phase 2 Orphan Disease Therapy with XOMA Corporation and Name Change to Rezolute, Inc.
AntriaBio Announces Exclusive License Agreement for a Phase 2 Orphan Disease Therapy with XOMA Corporation and Name Change to Rezolute, Inc. LOUISVILLE, Colorado, December 7, 2017 - (GLOBE NEWSWIRE) - Rezolute, Inc. ("Rezolute" or the "Company") (OTCQB: ANTB), a clinical stag
Read more →RZLTAntriaBio Announces Selection of Lead Oral Plasma Kallikrein Inhibitor Candidates for the Treatment of Diabetic Retinopathy, Diabetic Macular Edema and Hereditary Angioedema
AntriaBio Announces Selection of Lead Oral Plasma Kallikrein Inhibitor Candidates for the Treatment of Diabetic Retinopathy, Diabetic Macular Edema and Hereditary Angioedema LOUISVILLE, Colorado, Oct. 17, 2017 - (GLOBE NEWSWIRE) - AntriaBio, Inc. ("AntriaBio" or the "Company")
Read more →RZLTAntriaBio Appoints Nektar's Chief Financial Officer to its Board of Directors LOUISVILLE, CO - (Marketwired)
AntriaBio Appoints Nektar's Chief Financial Officer to its Board of Directors LOUISVILLE, CO - (Marketwired) - October 9, 2017 - AntriaBio, Inc. ("AntriaBio or the "Company") (OTCQB: ANTB), a biopharmaceutical company specializing in the development of innovative drug therapies
Read more →RZLTAntriaBio Appoints Dr. Robert Bhisitkul to its Scientific Advisory Board
AntriaBio Appoints Dr. Robert Bhisitkul to its Scientific Advisory Board LOUISVILLE, Colorado, Oct. 04, 2017 - (GLOBE NEWSWIRE) - AntriaBio, Inc. ("The Company") (OTCQB: ANTB), a biopharmaceutical company focused on developing platform technologies to target significant unmet me
Read more →RZLTAntriaBio and ActiveSite Pharmaceuticals Announce License and Development Agreement for Plasma Kallikrein Inhibitors LOUISVILLE, CO - (Marketwired)
AntriaBio and ActiveSite Pharmaceuticals Announce License and Development Agreement for Plasma Kallikrein Inhibitors LOUISVILLE, CO - (Marketwired) - August 7, 2017 - AntriaBio, Inc. ("AntriaBio") (OTCQB: ANTB) and ActiveSite Pharmaceuticals ("ActiveSite") today announced that
Read more →RZLTAntriaBio Announces First Patient Dosed in Phase 1 Clinical Study of AB101 LOUISVILLE, CO - (Marketwired)
AntriaBio Announces First Patient Dosed in Phase 1 Clinical Study of AB101 LOUISVILLE, CO - (Marketwired) - July 25, 2017 - AntriaBio, Inc. ("AntriaBio or the "Company") (OTCQB: ANTB), a biopharmaceutical company specializing in the development of innovative drug therapies to im
Read more →RZLTAntriaBio Announces $13 Million Close of Private Placement Transaction and Plan to Dose First Patient with AB101 This Month LOUISVILLE, CO - (Marketwired)
AntriaBio Announces $13 Million Close of Private Placement Transaction and Plan to Dose First Patient with AB101 This Month LOUISVILLE, CO - (Marketwired) - July 17, 2017 - AntriaBio, Inc. ("AntriaBio or the "Company") (OTCQB: ANTB), a clinical stage biopharmaceutical company s
Read more →RZLTAntriaBio Files Investigational New Drug Application for Once-Weekly Basal Insulin AB101 LOUISVILLE, CO - (Marketwired)
AntriaBio Files Investigational New Drug Application for Once-Weekly Basal Insulin LOUISVILLE, CO - (Marketwired) - June 5, 2017 - AntriaBio, Inc. ("AntriaBio or the "Company") (OTCQB: ANTB), a biopharmaceutical company specializing in the development of innovative drug therapie
Read more →RZLTAntriaBio Formally Engages CRO for the Conduct of its Phase I First-in-Human Clinical Trial of AB101 LOUISVILLE, CO - (Marketwired)
AntriaBio Formally Engages CRO for the Conduct of its Phase I First-in-Human Clinical Trial of AB101 LOUISVILLE, CO - (Marketwired) - May 1, 2017 - AntriaBio, Inc. ("AntriaBio or the "Company") (OTCQB: ANTB), a biopharmaceutical company specializing in the development of innovat
Read more →RZLTAntriaBio Appoints Two Pharmaceutical Executives to its Board of Directors LOUISVILLE, CO - (Marketwired)
AntriaBio Appoints Two Pharmaceutical Executives to its Board of Directors LOUISVILLE, CO - (Marketwired) - March 22, 2017 - AntriaBio, Inc. ("AntriaBio or the "Company") (OTCQB: ANTB), a biopharmaceutical growth company specializing in the development of innovative drug therapi
Read more →RZLTAntriaBio Announces Offer to Amend Warrants to Purchase Shares of Common Stock LOUISVILLE, CO
AntriaBio Announces Offer to Amend Warrants to Purchase Shares of Common Stock LOUISVILLE, CO - December 15, 2016 - AntriaBio, Inc. ("AntriaBio" or the "Company") (OTCQB: ANTB), a biopharmaceutical corporation focused on developing novel extended release therapies, announced tod
Read more →RZLTAntriaBio Announces Formation of Subsidiary and Plan to Raise Capital in South Korea Company Targeting Substantial Capital Raise in South Korea in Q4 2016 LOUISVILLE, CO
AntriaBio Announces Formation of Subsidiary and Plan to Raise Capital in South Korea Company Targeting Substantial Capital Raise in South Korea in Q4 2016 LOUISVILLE, CO - September 22, 2016 - AntriaBio, Inc. ("AntriaBio" or the "Company") (OTCQB: ANTB), a biopharmaceutical cor
Read more →RZLTAntriaBio Announces $12 Million Private Placement LOUISVILLE, CO
AntriaBio Announces $12 Million Private Placement LOUISVILLE, CO - June 29, 2016 - AntriaBio, Inc. ("AntriaBio" or the "Company") (OTCQB: ANTB), a biopharmaceutical corporation focused on developing novel extended release therapies, announced today that it has successfully raise
Read more →RZLTAntriaBio Announces Preclinical Proof of Concept for Once-Weekly Basal Insulin AB101 in Diabetic Miniature Swine LOUISVILLE, CO - 06/22/16 - AntriaBio, Inc. ("AntriaBio" or the "Company") (OTCQB: ANTB), a biopharmaceutic
AntriaBio Announces Preclinical Proof of Concept for Once-Weekly Basal Insulin AB101 in Diabetic Miniature Swine LOUISVILLE, CO - 06/22/16 - AntriaBio, Inc. ("AntriaBio" or the "Company") (OTCQB: ANTB), a biopharmaceutical corporation developing novel extended release therapies
Read more →RZLTAntriaBio Announces Appointment of Michael Deperro as Vice President of Operations LOUISVILLE, CO - (MarketWired)
AntriaBio Announces Appointment of Michael Deperro as Vice President of Operations LOUISVILLE, CO - (MarketWired) - January 6, 2016 - AntriaBio, Inc. ("AntriaBio" or the "Company") (OTCQB: ANTB), a biopharmaceutical corporation developing novel extended release therapies, announ
Read more →RZLTAntriaBio Announces First Close of Private Placement Transaction Financing Round Led By Insiders LOUISVILLE, CO - 12/10/15 - AntriaBio, Inc. ("AntriaBio" or the "Company") (OTCQB: ANTB), a biopharmaceutical corporation d
AntriaBio Announces First Close of Private Placement Transaction Financing Round Led By Insiders LOUISVILLE, CO - 12/10/15 - AntriaBio, Inc. ("AntriaBio" or the "Company") (OTCQB: ANTB), a biopharmaceutical corporation developing novel extended release therapies, announced toda
Read more →RZLTAntriaBio Receives Notice of Allowance on Patent Covering Microsphere Drug Delivery Platform LOUISVILLE, CO - 11/17/15 - AntriaBio, Inc. ("AntriaBio" or the "Company") (OTCQB: ANTB), a biopharmaceutical corporation devel
AntriaBio Receives Notice of Allowance on Patent Covering Microsphere Drug Delivery LOUISVILLE, CO - 11/17/15 - AntriaBio, Inc. ("AntriaBio" or the "Company") (OTCQB: ANTB), a biopharmaceutical corporation developing novel extended release therapies, announced that it has receiv
Read more →RZLTINVESTOR PRESENTATION ex99_1.htm EXHIB IT 99.1
INVESTOR PRESENTATION ex99_1.htm EXHIB IT 99.1
Read more →RZLTAntriaBio Announces New Product Candidate, AB301, a Weekly GLP-1 Agonist and Basal Insulin Combination, for Type 2 Diabetes LOUISVILLE, CO - 09/16/15 - AntriaBio, Inc. ("AntriaBio" or the "Company") (OTCQB: ANTB), a biop
AntriaBio Announces New Product Candidate, AB301, a Weekly GLP-1 Agonist and Basal Insulin Combination, for Type 2 Diabetes LOUISVILLE, CO - 09/16/15 - AntriaBio, Inc. ("AntriaBio" or the "Company") (OTCQB: ANTB), a biopharmaceutical corporation developing novel extended releas
Read more →RZLTAntriaBio Appoints David F. Welch, Ph.D. to its Board of Directors LOUISVILLE, CO - (Marketwired)
AntriaBio Appoints David F. Welch, Ph.D. to its Board of Directors LOUISVILLE, CO - (Marketwired) - June 29, 2015 - AntriaBio, Inc. ("AntriaBio or the "Company") (OTCQB: ANTB), a biopharmaceutical corporation focused on developing novel extended release therapies, announced toda
Read more →RZLTAntriaBio to Present New Preclinical Data at the American Diabetes Association 75 th Scientific Sessions Company to present preclinical data for its lead product candidate, AB101, a potential once-weekly basal insulin in
AntriaBio to Present New Preclinical Data at the American Diabetes Association 75th Company to present preclinical data for its lead product candidate, AB101, a potential once-weekly basal insulin in development for type 1 and type 2 diabetes- LOUISVILLE, CO - May 11, 2015 - A
Read more →RZLTAntriaBio Announces Appointment of Dr. Hoyoung Huh as Chairman of Scientific Advisory Board and Business Development LOUISVILLE, CO and
AntriaBio Announces Appointment of Dr. Hoyoung Huh as Chairman of Scientific Advisory Board and Business Development LOUISVILLE, CO and MENLO PARK, CA - January 8, 2015 - AntriaBio, Inc. ("AntriaBio or the "Company") (OTCQB: ANTB), a biopharmaceutical corporation focused on dev
Read more →RZLTAntriaBio Announces Completion of PK/PD Studies of AB101 in Two Species - AB101 positioned to be the first once-weekly basal insulin for diabetes patients - LOUISVILLE, CO
AntriaBio Announces Completion of PK/PD Studies of AB101 in Two Species - AB101 positioned to be the first once-weekly basal insulin for diabetes patients - LOUISVILLE, CO - January 7, 2015 - AntriaBio, Inc. ("AntriaBio or the "Company") (OTCQB: ANTB), a biopharmaceutical corpo
Read more →RZLTAntriaBio Announces $7 Million Private Placement LOUISVILLE, CO
AntriaBio Announces $7 Million Private Placement LOUISVILLE, CO - January 5, 2015 - AntriaBio, Inc. ("Company") (OTCQB: ANTB), a biopharmaceutical corporation focused on developing novel extended release therapies, announced today that it has successfully raised approximately $7
Read more →RZLTAntriaBio Extinguishes $44 Million Contingent Liability LOUISVILLE, CO
AntriaBio Extinguishes $44 Million Contingent Liability LOUISVILLE, CO - November 10, 2014 - AntriaBio, Inc. (OTCQB: ANTB) a biopharmaceutical corporation focused on developing novel extended release therapies, announced today that it has successfully extinguished $44 million of
Read more →RZLTAntriaBio Appoints Barry Sherman, M.D. to its Board of Directors
AntriaBio Appoints Barry Sherman, M.D. to its Board of Directors MENLO PARK, CA - July 14, 2014 - AntriaBio, Inc. (OTCQB: ANTB), a biopharmaceutical corporation focused on developing novel therapeutics to treat patients with diabetes and metabolic diseases, announced today the a
Read more →RZLTAntriaBio Appoints C. Ronald Kahn, M.D. to its Scientific Advisory Board
AntriaBio Appoints C. Ronald Kahn, M.D. to its Scientific Advisory Board MENLO PARK, CA - June 23, 2014 - AntriaBio, Inc. (OTCQB: ANTB) a biopharmaceutical corporation focused on developing novel therapeutics to treat patients with diabetes and metabolic diseases, announced the
Read more →RZLTAntriaBio, Inc. Establishes Manufacturing and Laboratory Facility in Colorado MENLO PARK, CA - (
AntriaBio, Inc. Establishes Manufacturing and Laboratory Facility in Colorado MENLO PARK, CA - (May 12, 2014) - AntriaBio, Inc. (OTCQB: ANTBD; ticker will revert back to ANTB on May 21, 2014), a biopharmaceutical corporation focused on developing novel therapeutics to treat pat
Read more →RZLTAntriaBio, Inc. Announces 1-for-6 Reverse Stock Split MENLO PARK, CA - (
AntriaBio, Inc. Announces 1-for-6 Reverse Stock Split MENLO PARK, CA - (May 1, 2014) - AntriaBio, Inc. (OTCQB: ANTB), a biopharmaceutical company focused on developing novel therapeutics to treat patients with diabetes and metabolic disease, announced that the Financial Industry
Read more →RZLTANTRIABIO, INC. ANNOUNCES $10M MILLION PRIVATE PLACEMENT MENLO PARK, CA - (
ANTRIABIO, INC. ANNOUNCES $10M MILLION PRIVATE PLACEMENT MENLO PARK, CA - (April 2, 2014) - AntriaBio, Inc. (OTCQB: ANTB), a biopharmaceutical company focused on developing novel therapeutics for the diabetes market, announced today that in the first quarter of 2014 it raised $1
Read more →RZLTAntriaBio Announces Closing of Bridge Financing -Company prepares to advance innovative lead product candidate, AB101, for the treatment of diabetes into clinical development- MENLO PARK, CA - (
AntriaBio Announces Closing of Bridge Financing -Company prepares to advance innovative lead product candidate, AB101, for the treatment of diabetes into clinical development- MENLO PARK, CA - (January 16, 2014) - AntriaBio, Inc. (OTCQB: ANTB) a biopharmaceutical company focuse
Read more →RZLTAntriaBio Granted European Patent Allowance for Method of Preparing Site- Specific Protein Conjugates Menlo Park, CA
AntriaBio Granted European Patent Allowance for Method of Preparing Site- Specific Protein Conjugates Menlo Park, CA - July 24, 2013 - AntriaBio, Inc. (OTCQB: ANTB), announced today that it has received an allowance from the European Patent Office for Patent Application No. 047
Read more →RZLTAntriaBio Initiates Effort to Raise up to $12 Million in a Private Placement Menlo Park, CA
AntriaBio Initiates Effort to Raise up to $12 Million in a Private Placement Menlo Park, CA - July 1, 2013 - AntriaBio, Inc. (OTCQB: ANTB), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of diabetes, announced today that as result of
Read more →RZLTAntriaBio Announces Stock Ticker Symbol Change to ANTB Menlo Park, CA - February 8 th , 2013 - AntriaBio, Inc. ("AntriaBio") today announced that FINRA has approved a change of the Company's stock ticker symbol. Effectiv
AntriaBio Announces Stock Ticker Symbol Change to ANTB Menlo Park, CA - February 8th, 2013 - AntriaBio, Inc. ("AntriaBio") today announced that FINRA has approved a change of the Company's stock ticker symbol. Effective today, the Company's common shares will commence trading on
Read more →RZLTAntriaBio, Inc. (A Development Stage Enterprise) Financial Statements As of
(A Development Stage Enterprise) Financial Statements As of December 31, 2011 and 2010, For the Year Ended December 31, 2011, And for the Periods from March 24, 2010 (Inception) to December 31, 2010 and 2011 Report of Independent Registered Public Accounting Firm Report of
Read more →RZLTAntriaBio Appoints Two Industry Leaders to its Management Team Menlo Park, CA - February 19th, 2013 - AntriaBio, Inc. is pleased to announce the appointment, on
AntriaBio Appoints Two Industry Leaders to its Management Team Menlo Park, CA - February 19th, 2013 - AntriaBio, Inc. is pleased to announce the appointment, on January 31, 2013, of two new members to its management team: Nevan Elam, AntriaBio's President and Chief Executive Off
Read more →RZLTAntriaBio Acquires Assets of PR Pharmaceuticals and Announces Intent to Merge with a Public Company Menlo Park, CA - January 7th, 2013 -AntriaBio, Inc., a biopharmaceutical company developing novel therapeutics for the d
AntriaBio Acquires Assets of PR Pharmaceuticals and Announces Intent to Merge with a Menlo Park, CA - January 7th, 2013 -AntriaBio, Inc., a biopharmaceutical company developing novel therapeutics for the diabetes market, is pleased to announce the acquisition of the significant
Read more →Competitive Position
How RZLT ranks across every disease it competes inCompetitive Position is a premium feature
See how RZLT ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial